Mallinckrodt/NeoRx agreement
Executive Summary
International Minerals & Chemical subsidiary Mallinckrodt acquires minority equity position in Seattle-based monoclonal antibody research firm NeoRx. Mallinckrodt will recieve "certain exclusive technology, product development and marketing rights in the field of radioisotopic imaging agents utilizing monoclonal antibodies," a March 18 release notes. Under the agreement, Mallinckrodt will get access to diagnostic products stemming from NeoRx research in the monoclonal antibody area.